Medicine details

ImageMepcort 1gm
NameMepcort 1gm
DosageInjection
Generic NameMethyl Prednisolone Sodium Succinate
Classes Dermatological/Topical Agent
Respiratory Agent
Antirheumatic
Glucocorticoid
Antiallergic Agent
Diseases Allergy
Arthritis
Asthma
Blood Disorder
Inflammatory Disease
Skin Infection
CompanyGlobe Pharmaceuticals Ltd.

Drug Package Details

Strength1 gm/vial
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack1,000.00
Cost per pack880.00
Package unit1 gm combipack
Price per unit1,000.00
Cost per unit880.00
Discount0
Coupon
Remarks

Methyl Prednisolone Sodium Succinate

Methyl Prednisolone Sodium Succinate belongs to a class of drugs, called the glucocorticoids. It is a synthetic glucocorticoid. Natural glucocorticoids (hydrocortisone and cortisone), which have salt-retaining characteristics, are employed in adrenocortical deficit replacement therapy. Their synthetic analogs are largely employed for anti-inflammatory actions in a variety of organ system illnesses. Glucocorticoids have a wide range of metabolic consequences. Furthermore, they alter the immune system's reaction to a variety of stimuli.

 

Methyl Prednisolone Sodium Succinate is available in several strengths and packages for intravenous or intramuscular administration. This dosage form is to be used when oral administration is not feasible. It is indicated for a number of health conditions-

  • Allergic States- asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness
  • Dermatologic Diseases- Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
  • Endocrine Disorders
  • Gastrointestinal diseases: In regional enteritis (systemic therapy) and ulcerative colitis, to help the patient get through a critical time of the disease.
  • Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Black fan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
  • Neoplastic Diseases: For palliative management of: leukemias and lymphomas.
  • Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy.
  • Ophthalmic Diseases: Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids.
  • Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
  • Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

 

  • Methylprednisolone can be given intramuscularly, intravenously, or as an IV infusion. To administer by intramuscular or intravenous injection, prepare the solution according to the directions for reconstitution. Several minutes may be required to provide the desired dose intravenously. The suggested dose of Methylprednisolone Sodium Succinate for Injection, USP is 30 mg/kg delivered intravenously over at least 30 minutes when high dose therapy is desired. For a total of 48 hours, this dose can be repeated every 4 to 6 hours. High-dose corticosteroid medication should only be continued until the patient's condition has stabilized, which is usually 48 to 72 hours.
  • In other cases, the initial dose of Methylprednisolone will range from 10 to 40 mg, depending on the clinical condition being treated. Larger doses may be needed to treat severe, acute diseases in the near term. The initial dose should be administered intravenously over several minutes. Following that, at intervals specified by the patient's response and clinical state, more doses may be administered intravenously or intramuscularly. Corticoid therapy is a supplement to, not a replacement for, traditional treatment.

     

  • The daily dose for acute exacerbations of multiple sclerosis is 160 mg three times a day for three days. The intravenous infusion of methylprednisolone powder for injection/infusion should last at least 30 minutes.

  • The starting dose of Methylprednisolone in pediatric patients varies based on the condition being treated. The initial dose is 0.11-1.6 mg per day, divided into three or four doses. For infants and children, dosage may be reduced, although it should be determined more by the severity of the ailment and the patient's response than by age or size, and should not be less than 0.5 mg per kg per 24 hours.

Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension etc.

Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing etc.

Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes.

Gastrointestinal: Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis.

Musculoskeletal: Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intra-lesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis.

Neurologic/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia.

  • The formulation contains Benzoyl Alcohol, which is potentially toxic when administered locally to neural tissue. Therefore it must not be administered intrathecally.
  • There have been a few cases of mortality linked to exposure to high quantities of benzyl alcohol, mostly in premature newborns. When compared to the quantity of benzyl alcohol obtained in benzyl alcohol-containing flush solutions, the amount of benzyl alcohol in pharmaceuticals is usually regarded small.
  • Heat is a problem for this product, as it is for many other steroid formulations. As a result, it should not be autoclaved when the exterior of the vial needs to be sterilized.
  • Because the size of the dose and the duration of treatment affect the risk of glucocorticoid-related problems, a risk/benefit decision about the amount and duration of treatment, as well as whether daily or intermittent therapy should be utilized, must be made in each instance.
  • Patients undergoing corticosteroid medication, most commonly for chronic illnesses, have been documented to develop Kaposi's sarcoma. Clinical improvement may occur if corticosteroids are stopped.
  • Corticosteroids, in both little and large dosages, can raise blood pressure, promote salt and water retention, and cause potassium excretion to increase.
  • Corticosteroids can produce reversible Hypothalamic-pituitary adrenal  axis suppression with the potential for gluco-corticosteroid insufficiency after withdrawal of treatment.
  • Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, and Toxoplasma.
  • Patients on corticosteroids are more susceptible to infections than healthy people.

Contraindication

  • Methyl Prednisolone Sodium Succinate Sterile Powder is contraindicated in patients with known hypersensitivity to the product and its constituents.
  • Methyl Prednisolone Sodium Succinate Sterile Powder is contraindicated for intrathecal administration. Reports of severe medical events have been associated with this route of administration.

There is no known contraindications of Methyl Prednisolone Sodium Succinate in terms of food and drinks.

  • Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.
  • Methyl Prednisolone Sodium Succinate is contraindicated for use in premature infants because the formulation contains benzyl alcohol.